The Idiopathic Thrombocytopenic Purpura Therapeutics Market is Forecast to Show Moderate Growth until 2019

Wednesday 18 April 2012, Amsterdam

The “Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics - Pipeline Assessment and Market Forecasts to 2019” report is an essential source of information and analysis on the global ITP therapeutics market, identifying the key trends shaping and driving the market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global ITP therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts.

The Idiopathic Thrombocytopenic Purpura Therapeutics Market is Forecast to Show Moderate Growth until 2019

This analysis estimated the Idiopathic Thrombocytopenic Purpura (ITP) therapeutics market was worth $299.06m in 2011. It is forecast to show moderate growth at a Compound Annual Growth Rate (CAGR) of 5.38% for the next eight years to reach $454.95m by 2019. The market witnessed significant growth during 2006-2011 owing to the launch of Nplate (romiplostim) in 2008 in the US and in Europe in 2009. In addition to this, Promacta/Revolade (eltrombopag) was launched in the US in 2009 and in Europe in 2010. The moderate growth in the ITP therapeutics market can be attributed to the strong performance of the both of these products during the forecast period. The expected launch of IGIV3I 10% Grifols will also contribute to the growth of the market during the forecast period.

The Idiopathic Thrombocytopenic Purpura Therapeutics Market has Low Unmet Need with Potential for Cost Effective Therapies with Better Safety Profiles

The current ITP therapeutics market consists of various generic and few branded products. The major classes of drugs used for the treatment of ITP include corticosteroids, Intravenous Immunoglobulins (IVIG), anti-D immunoglobulins and Thrombopoetin Receptor Agonists (TPO-RA). Corticosteroids, IVIG, anti-D immunoglobulins and IVRhIG are considered to be the first-line treatment options and Imuran (azathioprine), cyclosporine A, TPO-RA and Mabthera (off-label) are used as second-line therapeutic agents for ITP. The standard treatment therapies are unable to significantly modify the natural course of the disease by avoiding its chronic evolution. However, the thrombopoetin receptor agonists, Promacta/Revolade and Nplate, represent a major advancement in ITP treatment. The traditional therapies for ITP focus on reducing platelet destruction; whereas thrombopoietic agents have the ability to increase platelet counts of patients with ITP. These agents have changed the treatment paradigm for ITP.

Pipeline Dominated by Thrombopoetin Receptor Agonists (TPO-RA) Set to Change the Traditional Treatment Pattern

The developmental pipeline for ITP is strong and consists of novel agents in the late stages of clinical development. About 84% of the molecules in the pipeline are in late stages of development. 17% of these molecules are in Phase III and 67% in Phase II. The early stage pipeline constitutes 16% of the total ITP therapeutics pipeline. There is only one molecule each in Phase I/II and Pre-clinical, each contributing to 8 % of the pipeline. The First-In-Class (FIC) pipeline candidates that are present in the various phases of development will further lead to a change in the traditional treatment pattern of ITP.